Global Antimicrobial Resistance Market Size Study, By Drug Class (Combination Therapies, Tetracyclines, Cephalosporins), By Indication (Complicated Urinary Tract Infections, Blood Stream Infections, Community Acquired Pneumonia), By Mechanism of Action (P

Global Antimicrobial Resistance Market Size Study, By Drug Class (Combination Therapies, Tetracyclines, Cephalosporins), By Indication (Complicated Urinary Tract Infections, Blood Stream Infections, Community Acquired Pneumonia), By Mechanism of Action (Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors), and Regional Forecasts 2022-2032

Global Antimicrobial Resistance Market is valued approximately at USD 4.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.6% over the forecast period 2024-2032. Antimicrobial resistance (AMR) represents a profound challenge in contemporary healthcare, driven predominantly by the misuse and overuse of antibiotics. This misuse is rampant, particularly in low- and middle-income countries where regulatory frameworks are often weak or poorly enforced, leading to overprescribing and unregulated antibiotic use. Consequently, this contributes to the escalating demand for novel antibiotics capable of combating resistant bacterial infections. The urgent need for new antibiotics that can overcome antimicrobial resistance stems from the growing ineffectiveness of existing drugs. This resistance incurs substantial economic costs and places significant burdens on healthcare systems, often resulting in prolonged hospital stays and intensive care requirements. Antimicrobial resistance arises when microorganisms such as bacteria, fungi, and viruses develop resistance to drugs designed to kill them, posing severe threats to global health by making infections harder to treat and increasing the risk of disease spread, severe illness, and mortality.

Several factors propel the growth of the antimicrobial resistance market. The misuse and overuse of antibiotics, combined with the rising prevalence of difficult-to-treat bacterial infections, are primary drivers. The World Health Organization (WHO) has highlighted antimicrobial resistance as one of the top ten global public health threats, underscoring the urgent need for novel antibiotics. Complicated infections such as urinary tract infections (cUTIs) and hospital-acquired pneumonias caused by resistant bacteria exemplify the challenge, as they involve pathogens with limited treatment options, necessitating the development of new antibiotics to address these critical needs. The market is also bolstered by significant investments from key players focused on developing and launching new antibiotics. Products like Dificid, Recarbrio, Zerbaxa, and others are increasingly adopted in developed and some developing countries, driven by their effectiveness against resistant bacteria. However, the high cost associated with these novel antibiotics, due to complex R&D processes and stringent regulations, poses a significant market restraint. Furthermore, increased awareness of antibiotic resistance and substantial funding for developing new antibiotics present lucrative growth opportunities. Collaborations and partnerships among key players further boost market prospects.

The key region in the Antimicrobial Resistance Market includes North America, Europe, Asia Pacific, Latin America, Middle East & Africa. In 2023, North America dominates the antimicrobial resistance market, attributed to the presence of major industry players, advanced healthcare infrastructure, and the launch of novel antibiotics. the region's robust healthcare infrastructure and advanced pharmaceutical industry enable extensive research and development in combating AMR. Leading pharmaceutical companies based in the United States and Canada spearhead innovation in antibiotics and alternative therapies, supported by significant investments in drug discovery and clinical trials. In addition, North America's stringent regulatory frameworks ensure rigorous testing and approval processes for new antimicrobial agents, maintaining high standards of efficacy and safety. Moreover, widespread awareness campaigns and public health initiatives across the continent emphasize responsible antibiotic use and infection prevention strategies, aiming to curb the rise of resistant pathogens. The Asia-Pacific region is expected to witness the highest growth rate, driven by excessive antibiotic misuse, rising healthcare awareness, and the adoption of novel antibiotic medications in countries like India and China.

Major market players included in this report are:

Alkem Laboratories Ltd

Innoviva, Inc.

Pfizer Inc.

Merck & Co., Inc.

Acurx Pharmaceuticals, Inc.

Basilea Pharmaceutica Ltd

Cumberland Pharmaceuticals Inc.

Wockhardt Limited

Paratek Pharmaceuticals, Inc.

Nabriva Therapeutics plc

The detailed segments and sub-segment of the market are explained below:

By Drug Class

Combination Therapies

Tetracyclines

Cephalosporins

Glycopeptides and Lipoglycopeptides

Oxazolidinones

Others

By Indication

Complicated Urinary Tract Infections (cUTI)

Blood Stream Infections

Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Hospital Acquired Bacterial Pneumonia and Ventilator Acquired Bacterial Pneumonia (HABP and VABP)

Community Acquired Pneumonia (CAP)

Others

By Mechanism of Action

Protein Synthesis Inhibitors

Cell Wall Synthesis Inhibitors

Others

By Pathogen

Klebsiella pneumoniae

Pseudomonas aeruginosa

Staphylococcus aureus

Enterococcus Spp

Others

Escherichia coli

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand-side and supply-side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.